News & Media

Press release
Medivir has completed a successful pre-IND meeting with the FDA

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release
Medivir to present at the Erik Penser Bank Healthcare Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release
Medivir recruits Pia Baumann as new Chief Medical Officer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release
Medivir to present at the Redeye Life Science Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release
Medivir presents new data on additive efficacy of fostrox in combination with anti-PD1 in nonclinical tumor models at the SITC Immunotherapy Conference

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release Regulatory
MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2022

The measures to increase the pace of patient recruitment have yielded results. The Fostrox study is now progressing as expected. July...

Read more
Press release
Nomination Committee of Medivir appointed

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the nomination committee now has been appointed ahead of the...

Read more
Press release
Medivir to present at the H.C. Wainwright 24th Annual Global Investment Conference

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release
Medivir to present data on additive efficacy of fostrox in combination with anti-PD1 in nonclinical tumor models at the SITC 2022 Annual Meeting

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of...

Read more
Press release
Medivir to present at the Pareto Securities´ Healthcare conference

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the Pareto Securities´ Healthcare conference...

Read more
Press release
Medivir to present at the Erik Penser Bank Company Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company will present at the Erik Penser Bank Company...

Read more
Press release Regulatory
MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2022

The clinical development of fostrox remains our focus  April – June Financial summary for the quarter Net turnover amounted to SEK...

Read more